These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

920 related articles for article (PubMed ID: 20614180)

  • 1. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
    Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM
    Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH.
    Joosse SA; van Beers EH; Tielen IH; Horlings H; Peterse JL; Hoogerbrugge N; Ligtenberg MJ; Wessels LF; Axwijk P; Verhoef S; Hogervorst FB; Nederlof PM
    Breast Cancer Res Treat; 2009 Aug; 116(3):479-89. PubMed ID: 18704682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
    Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
    Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors.
    Joosse SA; Brandwijk KI; Mulder L; Wesseling J; Hannemann J; Nederlof PM
    Genes Chromosomes Cancer; 2011 Feb; 50(2):71-81. PubMed ID: 21104783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
    Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Sánchez L; Rivas C; Benítez J
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3606-14. PubMed ID: 14506147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping.
    Oldenburg RA; Kroeze-Jansema K; Meijers-Heijboer H; van Asperen CJ; Hoogerbrugge N; van Leeuwen I; Vasen HF; Cleton-Jansen AM; Kraan J; Houwing-Duistermaat JJ; Morreau H; Cornelisse CJ; Devilee P
    Clin Cancer Res; 2006 Mar; 12(6):1693-700. PubMed ID: 16551851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors.
    Wessels LF; van Welsem T; Hart AA; van't Veer LJ; Reinders MJ; Nederlof PM
    Cancer Res; 2002 Dec; 62(23):7110-7. PubMed ID: 12460933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The molecular pathology of hereditary breast cancer.
    Palacios J; Robles-Frías MJ; Castilla MA; López-García MA; Benítez J
    Pathobiology; 2008; 75(2):85-94. PubMed ID: 18544963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization.
    Jönsson G; Naylor TL; Vallon-Christersson J; Staaf J; Huang J; Ward MR; Greshock JD; Luts L; Olsson H; Rahman N; Stratton M; Ringnér M; Borg A; Weber BL
    Cancer Res; 2005 Sep; 65(17):7612-21. PubMed ID: 16140926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
    Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
    Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene.
    Ticha I; Kleibl Z; Stribrna J; Kotlas J; Zimovjanova M; Mateju M; Zikan M; Pohlreich P
    Breast Cancer Res Treat; 2010 Nov; 124(2):337-47. PubMed ID: 20135348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.
    Domchek SM; Gaudet MM; Stopfer JE; Fleischaut MH; Powers J; Kauff N; Offit K; Nathanson KL; Robson M
    Breast Cancer Res Treat; 2010 Jan; 119(2):409-14. PubMed ID: 19885732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subtypes of familial breast tumours revealed by expression and copy number profiling.
    Waddell N; Arnold J; Cocciardi S; da Silva L; Marsh A; Riley J; Johnstone CN; Orloff M; Assie G; Eng C; Reid L; Keith P; Yan M; Fox S; Devilee P; Godwin AK; Hogervorst FB; Couch F; ; Grimmond S; Flanagan JM; Khanna K; Simpson PT; Lakhani SR; Chenevix-Trench G
    Breast Cancer Res Treat; 2010 Oct; 123(3):661-77. PubMed ID: 19960244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics.
    Zuradelli M; Peissel B; Manoukian S; Zaffaroni D; Barile M; Pensotti V; Cavallari U; Masci G; Mariette F; Benski AC; Santoro A; Radice P
    Breast Cancer Res Treat; 2010 Nov; 124(1):251-8. PubMed ID: 20373018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
    Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
    Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double heterozygosity for mutations in the BRCA1 and BRCA2 genes in a breast cancer patient.
    Tsongalis GJ; Linfert DR; Johnson RC; Ackroyd R; Berman MM; Ricci A
    Arch Pathol Lab Med; 1998 Jun; 122(6):548-50. PubMed ID: 9625424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CGH analysis of familial non-BRCA1/BRCA2 breast tumors and mutation screening of a candidate locus on chromosome 17q11.2-12.
    Maguire P; Holmberg K; Kost-Alimova M; Imreh S; Skoog L; Lindblom A
    Int J Mol Med; 2005 Jul; 16(1):135-41. PubMed ID: 15942690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation.
    Alvarez S; Diaz-Uriarte R; Osorio A; Barroso A; Melchor L; Paz MF; Honrado E; Rodríguez R; Urioste M; Valle L; Díez O; Cigudosa JC; Dopazo J; Esteller M; Benitez J
    Clin Cancer Res; 2005 Feb; 11(3):1146-53. PubMed ID: 15709182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of molecular markers for BRCA1 and BRCA2 heterozygosity using gene expression profiling.
    Salmon AY; Salmon-Divon M; Zahavi T; Barash Y; Levy-Drummer RS; Jacob-Hirsch J; Peretz T
    Cancer Prev Res (Phila); 2013 Feb; 6(2):82-90. PubMed ID: 23341570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.